Javascript must be enabled to continue!
Growth hormone insensitivity: Mexican case report
View through CrossRef
Summary
Herein, we present a 14-year-old patient with short stature (134 cm) referred from Paediatrics to our department for complementary evaluation since growth hormone (GH) treatment failed to show any improvement. He was born premature and small for gestational age. Genital examination classified the patient as Tanner I–II with small penis and testicular size for his age. Biochemical analyses revealed normal GH levels with low serum insulin-like growth factor-1 (IGF-1). Molecular diagnosis confirmed several mutations in IGF1R and IGFALS, and so he was diagnosed with Laron Syndrome or GH insensibility and treated with IGF-1 substitutive therapy.
Learning points:
Evaluation of the GH/IGF-1 axis when short stature does not respond to conservative treatment must be included in the ordinary practice.
Laron Syndrome real incidence should be calculated once undiagnosed cases arise, as treatment, due to lack of market, is unaffordable.
Even when adulthood is reached, and no longitudinal growth can be achieved, still IGF-1 treatment in Laron Syndrome patients should be pursued as metabolic and protective derangements could arise.
Title: Growth hormone insensitivity: Mexican case report
Description:
Summary
Herein, we present a 14-year-old patient with short stature (134 cm) referred from Paediatrics to our department for complementary evaluation since growth hormone (GH) treatment failed to show any improvement.
He was born premature and small for gestational age.
Genital examination classified the patient as Tanner I–II with small penis and testicular size for his age.
Biochemical analyses revealed normal GH levels with low serum insulin-like growth factor-1 (IGF-1).
Molecular diagnosis confirmed several mutations in IGF1R and IGFALS, and so he was diagnosed with Laron Syndrome or GH insensibility and treated with IGF-1 substitutive therapy.
Learning points:
Evaluation of the GH/IGF-1 axis when short stature does not respond to conservative treatment must be included in the ordinary practice.
Laron Syndrome real incidence should be calculated once undiagnosed cases arise, as treatment, due to lack of market, is unaffordable.
Even when adulthood is reached, and no longitudinal growth can be achieved, still IGF-1 treatment in Laron Syndrome patients should be pursued as metabolic and protective derangements could arise.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Chest Wall Hydatid Cysts: A Systematic Review
Chest Wall Hydatid Cysts: A Systematic Review
Abstract
Introduction
Given the rarity of chest wall hydatid disease, information on this condition is primarily drawn from case reports. Hence, this study systematically reviews t...
Hydatid Cyst of The Orbit: A Systematic Review with Meta-Data
Hydatid Cyst of The Orbit: A Systematic Review with Meta-Data
Abstarct
Introduction
Orbital hydatid cysts (HCs) constitute less than 1% of all cases of hydatidosis, yet their occurrence is often linked to severe visual complications. This stu...
Immunoassay of serum polypeptide hormones by using 125I-labelled anti(-immunoglobulin G) antibodies
Immunoassay of serum polypeptide hormones by using 125I-labelled anti(-immunoglobulin G) antibodies
1. A technique for indirectly labelling antibodies to polypeptide hormones, by combining them with radioactively labelled anti-(immunoglobulin G) is described. (a) 125I-labelled an...
HER2 positive/hormone positive vs HER2 positive/hormone negative breast cancer: Clinical presentation, prognosis, and time to relapse—A retrospective cohort study.
HER2 positive/hormone positive vs HER2 positive/hormone negative breast cancer: Clinical presentation, prognosis, and time to relapse—A retrospective cohort study.
e13017
Background:
Breast cancer is among the most common malignancies globally, placing a substantial strain on healthcare systems an...
Growth Hormone Does Not Alter CYP2A6 Activity in Growth Hormone‐Deficient Children
Growth Hormone Does Not Alter CYP2A6 Activity in Growth Hormone‐Deficient Children
Abstract: A large number of metabolic alterations are increasingly being treated with growth hormone. Despite the fact that growth hormone is known to be the main regulator of sev...
Pseudohypoparathyroidism versus signaling disorder: A case report
Pseudohypoparathyroidism versus signaling disorder: A case report
Pseudohypoparathyroidism is a terminology used to describe a group of metabolic disorders characterized by parathyroid hormone resistance. Patients with pseudohypoparathyroidism ha...

